Biblio

Author Title [ Type

] Year

Filters: Author is Buxhofer-Ausch, Veronika [Clear All Filters]

Journal Article

Nikoloudis A, Buxhofer-Ausch V, Aichinger C, Binder M, Hasengruber P, Kaynak E, Wipplinger D, Milanov R, Strassl I, Stiefel O, et al. Impact of early cyclosporine A levels on acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation using in vivo T-cell depletion. Cytotherapy. 2024.

Völker LA, Kaufeld J, Balduin G, Merkel L, Kühne L, Eichenauer DA, Osterholt T, Hägele H, Kann M, Grundmann F, et al. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura. J Thromb Haemost. 2022.

Heibl S, Buxhofer-Ausch V, Schmidt S, Webersinke G, Lion T, Piringer G, Kuehr T, Wolf D, Melchardt T, Greil R, et al. A Phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha 2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia not achieving a deep molecular response (MR 4.5) - AGMT_CML 1. Hematol Oncol. 2020.

Nikoloudis A, Wagner H, Machherndl-Spandl S, Buxhofer-Ausch V, Strassl I, Stiefel O, Wipplinger D, Milanov R, Kaynak E, Hasengruber P, et al. Relapse protection following early CMV reactivation after HSCT is limited to HLA-C KIR ligand homozygous recipients. Transplant Cell Ther. 2021.

Kiladjian J-J, Marin FFerrer, Al-Ali HKathrin, Alvarez-Larran A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan A-M, et al. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Ann Hematol. 2024.

Buxhofer-Ausch V, Ausch C, Reiner A, Müllner-Ammer K, Schmid A, Kriwanek S, Sebesta C, Halwachs-Baumann G, Kriegshäuser G. SFRP1 promotor methylation analysis of FTA card touch-prep samples derived from colonic polyps. Exp Mol Pathol. 2020:104397.

Thiem U, Buxhofer-Ausch V, Kranewitter W, Webersinke G, Enkner W, Cejka D. Successful kidney transplantation in a patient with pre-existing chronic myeloid leukemia treated with imatinib. Am J Transplant. 2020.

Nikoloudis A, Neumann IJulia, Buxhofer-Ausch V, Machherndl-Spandl S, Binder M, Kaynak E, Milanov R, Nocker S, Stiefel O, Strassl I, et al. Successful SARS-CoV-2 mRNA Vaccination Program in Allogeneic Hematopoietic Stem Cell Transplant Recipients-A Retrospective Single-Center Analysis. Vaccines (Basel). 2023;11(10).

Strassl I, Windhager A, Machherndl-Spandl S, Buxhofer-Ausch V, Stiefel O, Weltermann A. TOP-PIC: a new tool to optimize pharmacotherapy and reduce polypharmacy in patients with incurable cancer. J Cancer Res Clin Oncol. 2023.

Völker LA, Brinkkoetter PT, Knöbl P, Krstic M, Kaufeld J, Menne J, Buxhofer-Ausch V, Miesbach W. Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab. J Thromb Haemost. 2020.